MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- BIOCON
- BIOCON LTD Announces Quarterly Results (2QFY19); Net Profit Up 501.9%
BIOCON LTD Announces Quarterly Results (2QFY19); Net Profit Up 501.9%
Fri, 9 Nov
BIOCON LTD has announced its results for the quarter ended September 2018. Here is a detailed performance review of the same:
BIOCON LTD Quarterly Financials
| No. of Mths Qtr. Ending | 3 Sep-17* | 3 Jun-18* | 3 Sep-18* | QoQ Change | YoY Change | |
|---|---|---|---|---|---|---|
| Net Sales | Rs m | 9,686 | 11,238 | 13,210 | 17.5% | 36.4% |
| Other income | Rs m | 508 | 688 | 544 | -20.9% | 7.1% |
| Turnover | Rs m | 10,194 | 11,926 | 13,754 | 15.3% | 34.9% |
| Expenses | Rs m | 7,863 | 8,860 | 9,814 | 10.8% | 24.8% |
| Gross profit | Rs m | 1,620 | 2,378 | 5,284 | 122.2% | 226.2% |
| Depreciation | Rs m | 936 | 991 | 1,122 | 13.2% | 19.9% |
| Interest | Rs m | 138 | 176 | 188 | 6.8% | 36.2% |
| Profit before tax | Rs m | 1,054 | 1,899 | 4,518 | 137.9% | 328.7% |
| Tax | Rs m | 425 | 521 | 732 | 40.5% | 72.2% |
| Profit after tax | Rs m | 629 | 1,378 | 3,786 | 174.7% | 501.9% |
| Gross profit margin | % | 16.7 | 21.2 | 40.0 | ||
| Effective tax rate | % | 40.3 | 27.4 | 16.2 | ||
| Net profit margin | % | 6.2 | 11.6 | 27.5 |
Interim results exclude extraordinary / exceptional items
Year-on-Year Performance:
- The company's operating income during the quarter grew 36.4% on a year-on-year (YoY) basis. The expenses were up by 24.8% YoY during the same period.
- The company's operating profit increased by 226.2% YoY during the quarter. Consequently, operating profit margins witnessed a growth and stood at 40.0% in 2QFY19 as against 16.7% in 2QFY18.
- Depreciation charges increased by 19.9% and finance costs increased by 36.2% YoY, respectively.
- Other income increased by 7.1% YoY during the quarter.
- Net profit for the quarter increased by 501.9% YoY. Net profit margins during the quarter increased from 6.2% in 2QFY18 to 27.5% in 2QFY19.
Quarter-on-Quarter Performance:
- The company's operating income during the quarter grew 17.5% on a quarter-on-quarter (QoQ) basis. The expenses were up by 10.8% QoQ during the same period.
- The company's operating profit increased by 122.2% QoQ during the quarter. Consequently, operating profit margins witnessed a growth and stood at 40.0% in 2QFY19 as against 21.2% in 1QFY18.
- Net profit for the quarter increased by 174.7% QoQ, while net profit margins increased from 11.6% in 1QFY18 to 27.5% in 2QFY19.
To see how BIOCON LTD has performed over the last eight quarters, please visit here.
BIOCON LTD Share Price Performance
Over the last one year, BIOCON LTD share price has moved up from Rs 400.7 to Rs 636.5, registering a Gain of Rs 235.9 or around 58.9%.
Meanwhile, the S&P BSE HEALTHCARE Index is trading at Rs 14,681.6 (up 1.0%). Over the last one year it has moved up from 13,987.8 to 14,681.6, a gain of 694 points (up 5.0%).
Overall, the S&P BSE SENSEX is up 5.3% over the year.
Current Valuations
At the current price of Rs 636.5, the price to earnings (P/E) ratio of BIOCON LTD stands at 50.6 times its trailing twelve months earnings, while its price to book value (P/BV) ratio stands at 7.4 times.
|
| |
Related Views on News
BIOCON LTD Announces Quarterly Results (3QFY19); Net Profit Up 169.2% (Quarterly Result Update)
Jan 28, 2019 | Updated on Jan 28, 2019For the quarter ended December 2018, BIOCON LTD has posted a net profit of Rs 2 bn (up 169.2% YoY). Sales on the other hand came in at Rs 15 bn (up 45.6% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.
BIOCON LTD Announces Quarterly Results (1QFY19); Net Profit Up 47.2% (Quarterly Result Update)
Jul 30, 2018 | Updated on Jul 30, 2018For the quarter ended June 2018, BIOCON LTD has posted a net profit of Rs 1 bn (up 47.2% YoY). Sales on the other hand came in at Rs 11 bn (up 20.4% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.
Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)
Feb 2, 2018Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.
Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)
Jun 23, 2017Net Profit lower due to exceptional items in the previous year.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
More Views on NewsMost Popular
Stocks that Could Be Out of Reach Post Elections(The 5 Minute Wrapup)
Apr 9, 2019It's a matter of time before the stocks catch the fancy of the markets and big investors.
3 Indian Stocks with Amazon-Like Potential(Profit Hunter)
Apr 10, 2019We have identified 3 stocks with huge wealth building potential which meet our 'Click of a Button' criteria.
This Company is Making a Big Comeback and You Can Now Profit from Its Example(The 5 Minute Wrapup)
Apr 10, 2019How Dell got its mojo back.
This is Why the Stock of Jubilant FoodWorks Went Up 1,160%(The 5 Minute Wrapup)
Apr 12, 2019This critical business strategy has enabled companies to scale their operations faster.
Pocketing Massive Gains with HDFC And HDFC Bank(Profit Hunter)
Apr 12, 2019Here's how one could have generated gains of Rs 59,250 in 10 days by trading HDFC and HDFC Bank with a capital of Rs 4 lakh.
More|
| |
BIOCON SHARE PRICE
Apr 22, 2019 09:29 AM
TRACK BIOCON
- Track your investment in BIOCON with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON BIOCON
BIOCON - FRESENIUS KABI ONCO. COMPARISON
COMPARE BIOCON WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster requests your view! Post a comment on "BIOCON LTD Announces Quarterly Results (2QFY19); Net Profit Up 501.9%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!